Subsequently, preclinical and clinical studies have shown that inhibiting IL-1β activity, either through a neutralizing IL-1β antibody like canakinumab or an IL-1 receptor antagonist like anakinra can enhance pancreatic beta-cell secretory function and reduce HbA1C levels in T2DM patients [8-10]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.